Company intelligence / Profile preview

Etubics Corporation

Seattle, Washington, United Statesdnb.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The Etubics Platform demonstrated the ability to overcome challenges seen with earlier viral vectors in Phase I and II trials. It enabled rapid development of immunotherapies and vaccines for cancer and infectious diseases. Clinical results showed promise but detailed efficacy data are not publicly available.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Gene delivery platform (adenovirus vector)Immunotherapies (immunotherapeutic drugs)Preventive vaccines
Industry: Biotech

Drug pipeline

1 asset

adeno-TWIST1 vaccine

Preclinical

Partnerships

National Cancer Institute – collaboration on novel immunotherapeutic cancer treatments in clinical trials.

Beyond the preview

Go deeper on Etubics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Etubics Corporation.

Explore the full profile